Clinical Trial Update: YF476 and Type I Gastric Carcinoids (Norway) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating YF476 for chronic atrophic gastritis with hypergastrinemia and Type I gastric carcinoids in Norway has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrophic Gastritis
• Hypergastrinemia
• Type Gastric Carcinoids

Drugs mentioned

• YF476

Snippet

Sponsor: Trio Medicines Ltd. | Conditions: Chronic Atrophic Gastritis, Hypergastrinemia | Phase 2 | Status: TERMINATED